Literature DB >> 24287875

Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis?

Waheed Abdelmonsef Mahmoud1, Nadia Abdelaaty Abdelkader, Amal Mansor.   

Abstract

PURPOSE: This study aimed to determine whether serum levels of nitric oxide metabolites (nitrates and nitrites) correlate with renal dysfunction in patients with liver cirrhosis and, moreover, to assess nitric oxide metabolite (NOx) power for predicting hepatorenal syndrome (HRS) in such patients.
METHODS: Among patients admitted to the Tropical Medicine Department, Ain Shams University Hospital, a total of 60 patients with chronic hepatitis C-related liver cirrhosis were included in this study. Patients were divided into three groups. Group I included 20 patients with compensated liver cirrhosis (CLC). Group II included 20 patients with decompensated liver cirrhosis (DLC). Group III included 20 patients with decompensated liver cirrhosis and HRS. Twenty healthy subjects with no clinical or laboratory evidence of liver disease were enrolled as a control group (group IV).
RESULTS: Patients with HRS had a higher mean nitrite levels followed by DLC, then CLC, and then controls. The sensitivity and specificity of NO metabolites (nitrites) were 100 % and 93.3 %, respectively, with accuracy of 95 % at cutoff value of 387 μmol/L for diagnosing patients with HRS. There was a highly significant statistical difference between patients positive and negative for nitrites as regards renal profile (p = 0.000).
CONCLUSION: A strong relation between nitrite cutoff value and renal dysfunction in liver cirrhosis has been found. Also, patients with HRS had higher mean serum nitrite levels than decompensated liver cirrhosis or compensated liver cirrhosis, raising the possibility of using nitrate and nitrite levels as a predictor for HRS in HCV-related liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24287875     DOI: 10.1007/s12664-013-0427-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  32 in total

1.  Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation.

Authors:  B Campillo; P N Bories; C Benvenuti; C Dupeyron
Journal:  J Hepatol       Date:  1996-11       Impact factor: 25.083

Review 2.  Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.

Authors:  Vicente Arroyo; Carlos Terra; Pere Ginès
Journal:  J Hepatol       Date:  2007-02-27       Impact factor: 25.083

3.  Quantitation of nitrate and nitrite in extracellular fluids.

Authors:  M B Grisham; G G Johnson; J R Lancaster
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

4.  Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state.

Authors:  J Heller; H Kristeleit; K A Brensing; R P Woitas; U Spengler; T Sauerbruch
Journal:  Scand J Gastroenterol       Date:  1999-03       Impact factor: 2.423

5.  Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients.

Authors:  Christoph Elsing; Sabine Harenberg; Wolfgang Stremmel; Thomas Herrmann
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

6.  Nitric oxide and renal functions in liver cirrhosis.

Authors:  Cansel Türkay; Ozlem Yönem; Osman Arikan; Esra Baskin
Journal:  Turk J Gastroenterol       Date:  2004-06       Impact factor: 1.852

Review 7.  Hepatorenal syndrome.

Authors:  Mónica Guevara; Juan Rodés
Journal:  Int J Biochem Cell Biol       Date:  2005-01       Impact factor: 5.085

8.  DNA deaminating ability and genotoxicity of nitric oxide and its progenitors.

Authors:  D A Wink; K S Kasprzak; C M Maragos; R K Elespuru; M Misra; T M Dunams; T A Cebula; W H Koch; A W Andrews; J S Allen
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

9.  Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction.

Authors:  Zeid Kayali; Jason Herring; Pedro Baron; Edson Franco; Okechukwu Ojogho; Jason Smith; Gregory Watkins; Douglas Smith; Victor Lamin; Thanh Hoang; Rajiv Sharma; Meleah Mathahs; Lawrance Sowers; Kyle E Brown; Warren N Schmidt
Journal:  J Gastroenterol Hepatol       Date:  2009-02-15       Impact factor: 4.029

Review 10.  Cardiac and vascular changes in cirrhosis: pathogenic mechanisms.

Authors:  HongQun Liu; Seyed Ali Gaskari; Samuel S Lee
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

View more
  2 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  Protective Effects of the Third Generation Vasodilatory Βeta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats.

Authors:  Ahmed Atwa; Rehab Hegazy; Rania Mohsen; Neamat Yassin; Sanaa Kenawy
Journal:  Open Access Maced J Med Sci       Date:  2017-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.